Next Article in Journal
Molluscicidal Activity of Methomyl and Cardenolide Extracts from Calotropis procera and Adenium arabicum Against the Land Snail Monacha cantiana
Previous Article in Journal
Kale Extract Increases Glutathione Levels in V79 Cells, but Does not Protect Them against Acute Toxicity Induced by Hydrogen Peroxide
Previous Article in Special Issue
Bio-Functional Constituents from the Stems of Liriodendron tulipifera
Open AccessReview

The Pharmacological Properties and Therapeutic Use of Apomorphine

by 1,2
1
Institute of Pathophysiology, Medical Faculty, University of Ljubljana, Zaloška 4, SI-1000 Ljubljana, Slovenia
2
Laboratory for Movement Disorders, Department of Neurological Disorders, University Clinical Centre Ljubljana, Zaloška 2, SI-1000 Ljubljana, Slovenia
Molecules 2012, 17(5), 5289-5309; https://doi.org/10.3390/molecules17055289
Received: 1 March 2012 / Revised: 22 April 2012 / Accepted: 25 April 2012 / Published: 7 May 2012
Apomorphine (APO) is an aporphine derivative used in human and veterinary medicine. APO activates D1, D2S, D2L, D3, D4, and D5 receptors (and is thus classified as a non-selective dopamine agonist), serotonin receptors (5HT1A, 5HT2A, 5HT2B, and 5HT2C), and α-adrenergic receptors (α1B, α1D, α2A, α2B, and α2C). In veterinary medicine, APO is used to induce vomiting in dogs, an important early treatment for some common orally ingested poisons (e.g., anti-freeze or insecticides). In human medicine, it has been used in a variety of treatments ranging from the treatment of addiction (i.e., to heroin, alcohol or cigarettes), for treatment of erectile dysfunction in males and hypoactive sexual desire disorder in females to the treatment of patients with Parkinson's disease (PD). Currently, APO is used in patients with advanced PD, for the treatment of persistent and disabling motor fluctuations which do not respond to levodopa or other dopamine agonists, either on its own or in combination with deep brain stimulation. Recently, a new and potentially important therapeutic role for APO in the treatment of Alzheimer’s disease has been suggested; APO seems to stimulate Ab catabolism in an animal model and cell culture, thus reducing the rate of Ab oligomerisation and consequent neural cell death. View Full-Text
Keywords: apomorphine; Alzheimer’s disease; dopamine agonist; erectile dysfunction; Parkinson’s disease apomorphine; Alzheimer’s disease; dopamine agonist; erectile dysfunction; Parkinson’s disease
Show Figures

Graphical abstract

MDPI and ACS Style

Ribarič, S. The Pharmacological Properties and Therapeutic Use of Apomorphine. Molecules 2012, 17, 5289-5309. https://doi.org/10.3390/molecules17055289

AMA Style

Ribarič S. The Pharmacological Properties and Therapeutic Use of Apomorphine. Molecules. 2012; 17(5):5289-5309. https://doi.org/10.3390/molecules17055289

Chicago/Turabian Style

Ribarič, Samo. 2012. "The Pharmacological Properties and Therapeutic Use of Apomorphine" Molecules 17, no. 5: 5289-5309. https://doi.org/10.3390/molecules17055289

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop